![Joseph Oliveto](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Joseph Oliveto
Amministratore Delegato presso MILESTONE PHARMACEUTICALS INC.
Patrimonio netto: 376 432 $ in data 30/06/2024
Profilo
Joseph G.
Oliveto is currently the President, Chief Executive Officer & Director at Milestone Pharmaceuticals, Inc. and the President & Chief Executive Officer at Milestone Pharmaceuticals USA, Inc. He previously held positions as the President, Chief Executive Officer & Director at Chelsea Therapeutics International Ltd., the Chief Executive Officer & Director at Galleon Pharmaceuticals, Inc., the Director-Global Alliance at Hoffmann-La Roche, Inc., and the Executive-in-Residence at Pappas Capital LLC.
Mr. Oliveto obtained his undergraduate degree and MBA from Rutgers State University of New Jersey.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
15/04/2024 | 285 176 ( 0.54% ) | 376 432 $ | 30/06/2024 |
Posizioni attive di Joseph Oliveto
Società | Posizione | Inizio |
---|---|---|
MILESTONE PHARMACEUTICALS INC. | Amministratore Delegato | 07/03/2017 |
Milestone Pharmaceuticals USA, Inc.
![]() Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Part of Milestone Pharmaceuticals, Inc., Milestone Pharmaceuticals USA, Inc. develops cardiovascular drugs. The company is based in Charlotte, NC. Joseph G. Oliveto has been the CEO of the company since 2017. | Amministratore Delegato | 07/03/2017 |
Precedenti posizioni note di Joseph Oliveto
Società | Posizione | Fine |
---|---|---|
Galleon Pharmaceuticals, Inc.
![]() Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | Amministratore Delegato | 01/06/2016 |
CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Amministratore Delegato | 23/06/2014 |
Pappas Capital LLC
![]() Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Corporate Officer/Principal | 30/06/2008 |
Hoffmann-La Roche, Inc.
![]() Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 01/01/2008 |
Formazione di Joseph Oliveto
Rutgers State University of New Jersey | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
MILESTONE PHARMACEUTICALS INC. | Health Technology |
Aziende private | 5 |
---|---|
Chelsea Therapeutics International Ltd.
![]() Chelsea Therapeutics International Ltd. BiotechnologyHealth Technology Chelsea Therapeutics International Ltd. acquires, develops and commercializes innovative products for the treatment of a variety of human diseases. The company was founded by Simon C. Pedder on June 17, 2005 and is headquartered in Charlotte, NC. | Health Technology |
Galleon Pharmaceuticals, Inc.
![]() Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | Health Technology |
Hoffmann-La Roche, Inc.
![]() Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Pappas Capital LLC
![]() Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Finance |
Milestone Pharmaceuticals USA, Inc.
![]() Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Part of Milestone Pharmaceuticals, Inc., Milestone Pharmaceuticals USA, Inc. develops cardiovascular drugs. The company is based in Charlotte, NC. Joseph G. Oliveto has been the CEO of the company since 2017. | Health Technology |
- Borsa valori
- Insiders
- Joseph Oliveto